[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Verve Therapeutics, Inc.\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":80},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,50],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":29,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":38,"lastUpdatePostDateStruct":39,"startDateStruct":42,"completionDateStruct":44,"leadSponsor":46,"locationsCount":49},"100528742","phase-1-a-study-of-verve-102-in-patients-with-familial-hypercholesterolemia-or-premature-coronary-artery-disease-100528742",false,"NCT06164730","A Study of VERVE-102 in Patients With Familial Hypercholesterolemia or Premature Coronary Artery Disease","Open-label, Phase 1b, Single Ascending Dose Study to Evaluate the Safety of VERVE-102 Administered to Patients With Heterozygous Familial Hypercholesterolemia or Premature Coronary Artery Disease Who Require Additional Lowering of Low-density Lipoprotein Cholesterol","Inclusion Criteria:\n\n* Diagnosis of HeFH or premature CAD\n\nExclusion Criteria:\n\n* Homozygous familial hypercholesterolemia\n* Active or history of chronic liver disease\n* Current treatment with PCSK9 inhibitor or prior treatment within specified timeframe\n* Clinically significant or abnormal laboratory values as defined by the protocol","ALL","18 Years","70 Years",{"count":20,"type":21},85,"ESTIMATED","INTERVENTIONAL",[24],"PHASE1","VT-10201 is an Open-label, Phase 1b, Single-ascending Dose Study That Will Evaluate the Safety of VERVE-102 Administered to Patients With Heterozygous Familial Hypercholesterolemia (HeFH) or Premature Coronary Artery Disease (CAD) Who Require Additional Lowering of LDL-C. VERVE-102 Uses Base-editing Technology Designed to Disrupt the Expression of the PCSK9 Gene in the Liver and Lower Circulating PCSK9 and LDL-C. This Study is Designed to Determine the Safety and Pharmacodynamic Profile of VERVE-102 in This Patient Population.",[27,28],"Heterozygous Familial Hypercholesterolemia","Premature Coronary Heart Disease",[30,31,32,33,34,35,36],"VERVE-102","Familial Hypercholesterolemia","Coronary Artery Disease","Dose Escalation","Gene Editing","Base Editing","heart-2","RECRUITING","2026-07-31",{"date":40,"type":41},"2026-08-03","ACTUAL",{"date":43,"type":41},"2024-04-30",{"date":45,"type":21},"2027-08",{"name":47,"class":48},"Verve Therapeutics, Inc.","INDUSTRY",27,{"id":51,"slug":52,"hasResults":11,"nctId":53,"briefTitle":54,"officialTitle":55,"acronym":4,"eligibilityCriteria":56,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":57,"targetDuration":4,"studyType":22,"phases":59,"briefSummary":60,"conditions":61,"keywords":65,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":72,"startDateStruct":74,"completionDateStruct":76,"leadSponsor":78,"locationsCount":79},"100550799","phase-1-phase-1b-study-of-verve-201-in-patients-with-refractory-hyperlipidemia-100550799","NCT06451770","Phase 1b Study of VERVE-201 in Patients With Refractory Hyperlipidemia","A Phase 1b Single Ascending Dose Study to Evaluate the Safety of VERVE-201 in Patients With Refractory Hyperlipidemia","Inclusion Criteria:\n\n* Refractory hypercholesterolemia\n* Refractory hypertriglyceridemia\n\nExclusion Criteria:\n\n* Active or history of chronic liver disease\n* Current treatment with monoclonal antibody targeting ANGPTL3 or prior treatment within specified timeframe\n* Clinically significant or abnormal laboratory values as defined by the protocol",{"count":58,"type":21},36,[24],"VT-20101 is an Open-label, Phase 1b, Single-ascending dose study that will evaluate the safety of VERVE-201 administered to patients with Refractory Hyperlipidemia.\n\nVERVE-201 uses base-editing technology designed to inactivate the expression of the ANGPTL3 gene in the liver and lower circulating low-density lipoprotein cholesterol (LDL-C) and triglycerides. This study is designed to determine the safety and pharmacodynamic profile of VERVE-201 in this patient population.",[62,63,64],"Hypercholesterolemia","Hypertriglyceridemia","Refractory Hyperlipidemia",[66,34,35,67,68,69,70,64,31],"VERVE-201","Refractory Hypercholesterolemia","ANGPTL3","ASCVD","Refractory Hypertriglyceridemia","2026-07-15",{"date":73,"type":41},"2026-07-17",{"date":75,"type":41},"2024-10-30",{"date":77,"type":21},"2027-12",{"name":47,"class":48},16,""]